Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hørehæmning, strategier og resultater i VA Akutafdelinger (HearVA-ED)

30. september 2026 opdateret af: VA Office of Research and Development

Implementering af HearVA (I-HearVA)

HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

HearVA is a randomized controlled trial to explore the utility and outcomes of providing point-of-care access to hearing-impaired Veterans, comparing an offer of personal amplifiers versus control in an environment where the clinical stakes are high. It addresses a knowledge gap about the utility of providing such hearing assistance during clinical encounters. The study measures whether providing personal amplifiers is acceptable to older patients, can improve hearing, enhance understanding of discharge instructions, and improve care transitions at discharge. If such a strategy is beneficial, this simple low-tech approach has great potential for implementation and wide dissemination. HearVA-ED has two phases - the first, which has been completed, established the feasibility and acceptability of research and procedures in the ED environment through a pilot efficacy study and the second phase will be to complete a larger more definitive efficacy study and a detailed implementation study resulting in a strategic approach that can be widely disseminated across all VA emergency departments throughout the United States. This second phase will use a mixed-methods, hybrid effectiveness-implementation design to implement and evaluate the hearing assistance intervention in six VA Emergency Department Sites (in different facilities across the country). Implementation will occur in four stages with variation in the starting sequence at each site: The first group of two VA emergency departments will initiate implementation with an efficacy trial; second group of two sites will initiate implementation with delivery and support of personal amplifiers after screening and randomization by a research assistant (Stage 1); the third group of two sites will initiate implementation with the entire implementation (Stage 2) and the presence of a research assistant to conduct discharge interviews; and all sites will progress from this sequence to Stage 3 - Sustainability - which is the full implementation without research assistant presence.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1050

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Lin T Tun
  • Telefonnummer: (646) 501-4132
  • E-mail: lin.tun@va.gov

Studiesteder

    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045-7211
        • Rekruttering
        • Rocky Mountain Regional VA Medical Center, Aurora, CO
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10010-5011
        • Rekruttering
        • VA NY Harbor Healthcare System, New York, NY
        • Ledende efterforsker:
          • Joshua Chodosh, MD MSHS
        • Kontakt:
        • Kontakt:
      • Syracuse, New York, Forenede Stater, 13210-2716
        • Aktiv, ikke rekrutterende
        • Syracuse VA Medical Center, Syracuse, NY
      • The Bronx, New York, Forenede Stater, 10468
        • Rekruttering
        • James J. Peters VA Medical Center, Bronx, NY
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705-3875
        • Rekruttering
        • Durham VA Medical Center, Durham, NC
        • Kontakt:
    • Texas
      • Dallas, Texas, Forenede Stater, 75216-7167
        • Rekruttering
        • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • English speaking
  • Emergency severity index criterion of 3 (medium), 4, or 5 (low acuity)
  • Hearing Handicap Inventory-Screen greater than or equal to 10 or positive answer to a single-item screening question
  • Capacity to consent to participate in research

Exclusion Criteria:

  • Inability to consent to participate in research
  • Emergency severity index criterion of 1-2 (high acuity)
  • Hearing Handicap Inventory-Screen less than 10 and negative answer to single item screening question
  • Inability to speak English
  • Using cochlear implants

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention: Personal Amplifier

Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department

The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED

Andre navne:
  • Lommetaler
Andet: Control: No Personal Amplifier

Consenting participants will be randomly assigned to the control group while receiving care in the emergency department

The control group will not receive personal amplifiers while they receive care in the ED

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Emergency department (ED) 3-day Readmissions
Tidsramme: 3-5 days after initial ED stay

The Investigators will determine whether patients have had an ED revisit within three days through CPRS review as well as a brief follow-up phone call 3-5 days after ED discharge

3-5 days after initial ED stay

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Emergency department (ED) 30-day Readmissions
Tidsramme: 30-35 days after initial ED stay

The Investigators will determine whether patients have had an ED revisit within 30 days through CPRS review as well as a brief follow-up phone call 30-35 days after ED discharge

30-35 days after initial ED stay
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During Emergency department (ED) Stay
Tidsramme: Duration of ED stay, average of 1 day

Participants will self-rate their quality of hearing, understanding, and communication using a six item questionnaire. Scored on a 10-point Likert scale (1 = do not agree at all; 10 = completely agree) the questions will be: When I talked to the doctors and nurses today ... (1) their voices were very clear; (2) I was able to hear the sounds that I wanted to hear; (3) noises did not cause a problem for my hearing; and (4) listening did not make me tired. Two additional statements will explicitly capture understanding: (5) I was able to understand what they said; and (6) I was able to understand without making an effort. Higher scores will indicate better communication and understanding with providers.

Duration of ED stay, average of 1 day
Patient-Rated Quality of Post-Discharge Care
Tidsramme: At time of discharge from ED, average 1 day

Patient-rated quality of post-discharge care using a three-item subset of the Care Transition Measure (CTM). The questions are scored on a 1-4 scale (1= strongly disagree; 4 = strongly agree): (1) The ED staff considered my preferences and those of my family or caregiver in deciding what my healthcare needs were for discharge; (2) Leaving the ED, I have a good understanding of the things I am responsible for in managing my health; (3) Leaving the ED, I clearly understand the purpose for each of my medications. Higher scores will indicate better discharge preparation.

At time of discharge from ED, average 1 day
Self-Reported Understanding of Discharge Instructions
Tidsramme: 3-5 days after initial ED stay

Investigators will gauge self-reported understanding of discharge instructions using semi-structured interview data compared to documented discharge data.

3-5 days after initial ED stay

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Joshua Chodosh, MD MSHS, VA NY Harbor Healthcare System, New York, NY

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. december 2021

Primær færdiggørelse (Anslået)

31. marts 2027

Studieafslutning (Anslået)

31. marts 2027

Datoer for studieregistrering

Først indsendt

24. august 2021

Først indsendt, der opfyldte QC-kriterier

30. august 2021

Først opslået (Faktiske)

31. august 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IIR 17-068-1
  • HX002421 (Andet bevillings-/finansieringsnummer: VA HSR&D)
  • 5I01HX002421-08 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .